CAMBRIDGE - Flagship Pioneering and ProFound Therapeutics, a Flagship-founded company pioneering the expanded human proteome to develop novel medicines for a multitude of diseases, today announced a collaboration to conduct foundational research to identify potential next-generation first-in-class therapies for the treatment of obesity.
The collaboration is the first initiated under Flagship's Pioneering Medicines strategic partnership with
Pioneering Medicines, Flagship's in house drug discovery and development unit, is responsible for leading the partnership with
'We are thrilled to be part of the Flagship and
'Since launching this unique alliance between Flagship and
Under this collaboration, ProFound will deploy its proprietary ProFoundry Platform in collaboration with Pioneering Medicines' drug development expertise to collectively discover novel proteins and evaluate their therapeutic relevance for the treatment of obesity. After early validation activities by ProFound,
'This agreement the first under our broader strategic partnership with Flagship is designed to push the boundaries of science to potentially unlock new protein therapeutics for obesity leveraging ProFound's proprietary discovery platform,' said
About Flagship Pioneering and Pioneering Medicines
Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its
Pioneering Medicines, Flagship Pioneering's in house drug development unit, is dedicated to conceiving and developing a broad portfolio of life-changing treatments for patients built from Flagship's innovative platforms. Harnessing the drug development expertise of its team together with the power of Flagship's multiple scientific platforms, Pioneering Medicines explores and identifies new product concepts which are then advanced jointly with Flagship's bioplatform companies. Pioneering Medicines also partners with external collaborators to apply its unique approach to partners' R&D priorities. These innovation supply chain partnerships are highly co-creative strategic alliances that accelerate therapeutic innovation by bringing together partners spanning the full spectrum of drug discovery, development, and production. Pioneering Medicines' current partners include
About ProFound Therapeutics
ProFound Therapeutics is discovering proteins hidden within the expanded human proteome to uncover novel drugs and drug targets, producing first-in-class medicines for a multitude of diseases. The company's ProFoundry Platform uses state-of-the-art protein detection technologies to systematically identify and validate proteins and dissect their therapeutic potential. The result is an ever-expanding database of tens of thousands of novel proteins, including their connectivity, functionality, and roles in health and disease. ProFound Therapeutics was founded in 2020 by Flagship Pioneering.
Contact:
Email: jzorbo@flagshippioneering.com
(C) 2024 Electronic News Publishing, source